Intellia Thera CS (NTLA)

$9.74 +0.68 (7.51%)
Market Cap 938.22M
Revenue (ttm) 57.88M
Net Income (ttm) -519.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -896.72%
Debt to Equity Ratio 0.00
Volume 5,913,100
Avg Vol 8,304,628
Day's Range N/A - N/A
Shares Out 115.83M
Stochastic %K 91%
Beta 2.13
Analysts Sell
Price Target $22.07

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
PMD777
PMD777 Dec. 4 at 11:33 PM
$NTLA when the letter drops we will know for sure- I hope it’s not after hours to avoid a gap
0 · Reply
_GoldenTrading
_GoldenTrading Dec. 4 at 11:11 PM
SNSE IS SQUEEZING!!! $ASPI $NTLA $PL $LYFT $SBUX x
0 · Reply
Iightning
Iightning Dec. 4 at 11:03 PM
1ightning® Premium Options Alert (Actionable) Ticker: $NTLA Contract: Dec 19 $10C Entry: 0.53 Exit: 0.95 Return: +80.34% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
VVDB
VVDB Dec. 4 at 11:02 PM
$NTLA Will explode once FDA restriction for the trial is cancelled. https://youtu.be/T-F5kWyuIXo?si=TfukXsjf7wpd9JtD
0 · Reply
svertical1
svertical1 Dec. 4 at 10:54 PM
$IBRX $CADL $NTLA $CRSP should have doubled today, if not more!
3 · Reply
GoldenBully
GoldenBully Dec. 4 at 9:58 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $NKLR $CL $NTLA $NOW (
0 · Reply
svertical1
svertical1 Dec. 4 at 9:35 PM
$VRTX $CRSP $XBI $NTLA If Vertex makes attempt to buy CRSP, they should offer: • $50 per share in cash ($4B) •1 share of Vertex for every 4 shares of CRSP (25M Vertex shares- or $11.5B) Total offer $15B (Cholesterol drug alone eventually pays for this, 100% rev on CASGEVY helps too) Use another $2B for rare disease Fast Track Trials for dozens of genetic diseases. This is where CRSP dropped the ball…Pipeline should be massive!
1 · Reply
Golden_Steer
Golden_Steer Dec. 4 at 8:53 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $RDW $NKLR $S $NTLA Limited
0 · Reply
svertical1
svertical1 Dec. 4 at 8:01 PM
$VRTX $CRSP $NTLA $EDIT Vertex is clear leader in: CF, SCD, TDT, Pain, Kidney, T1D Imagine then leading genetic engineering after CRSP buy🤞! Use their Billions to begin trials for the Top 100 genetic diseases. Keep 100%!of revenue! All Fast Tracked, with FDA onboard to Insure US Biotech remains preeminent over China and others.
1 · Reply
GoFrogs09
GoFrogs09 Dec. 4 at 6:44 PM
$NTLA was heavily shorted any news will make this run back to $15 👍
0 · Reply
Latest News on NTLA
The Short List — Top 10 Most Shorted Stocks Right Now

Nov 26, 2025, 11:34 AM EST - 8 days ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR CMBM HIMS HTZ LCID REPL SOC

2 Beaten-Down Stocks to Avoid Right Now

Nov 15, 2025, 9:35 AM EST - 19 days ago

2 Beaten-Down Stocks to Avoid Right Now

SRPT

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 10, 2025, 3:17 PM EST - 24 days ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 8, 2025, 5:13 PM EST - 26 days ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street

Nov 7, 2025, 8:45 AM EST - 27 days ago

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street

IOVA

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 5:46 AM EST - 27 days ago

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

Nov 2, 2025, 9:25 AM EST - 4 weeks ago

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 29, 2025, 5:11 PM EDT - 5 weeks ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Oct 27, 2025, 11:17 AM EDT - 5 weeks ago

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:38 AM EDT - 5 weeks ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 27, 2025, 7:30 AM EDT - 5 weeks ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Oct 24, 2025, 8:15 AM EDT - 5 weeks ago

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

4 Healthcare Stocks to Buy Now

Oct 12, 2025, 9:45 AM EDT - 7 weeks ago

4 Healthcare Stocks to Buy Now

CRSP RXRX VRTX

1 Stock Up by 63% This Year That Could Double, According to Wall Street

Oct 7, 2025, 9:45 AM EDT - 2 months ago

1 Stock Up by 63% This Year That Could Double, According to Wall Street

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:01 PM EDT - 2 months ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 1:57 PM EDT - 2 months ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 25, 2025, 9:52 AM EDT - 2 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Sep 19, 2025, 2:31 PM EDT - 2 months ago

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 18, 2025, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%

Sep 11, 2025, 3:45 AM EDT - 3 months ago

Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%

CRSP

Why big players are pouring millions in THIS biotech stock

Sep 1, 2025, 8:43 AM EDT - 3 months ago

Why big players are pouring millions in THIS biotech stock

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 15, 2025, 12:24 PM EDT - 3 months ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:17 PM EDT - 4 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Intellia (NTLA) Q2 Revenue Jumps 106%

Aug 7, 2025, 11:23 AM EDT - 4 months ago

Intellia (NTLA) Q2 Revenue Jumps 106%

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 4 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 4 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 4 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jul 18, 2025, 8:00 AM EDT - 4 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 6 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 29, 2025, 11:25 AM EDT - 6 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 7 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 7 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 1:57 PM EDT - 7 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 12, 2025, 9:07 AM EDT - 7 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:37 AM EDT - 7 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 7 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 7 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 8 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 8 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

PMD777
PMD777 Dec. 4 at 11:33 PM
$NTLA when the letter drops we will know for sure- I hope it’s not after hours to avoid a gap
0 · Reply
_GoldenTrading
_GoldenTrading Dec. 4 at 11:11 PM
SNSE IS SQUEEZING!!! $ASPI $NTLA $PL $LYFT $SBUX x
0 · Reply
Iightning
Iightning Dec. 4 at 11:03 PM
1ightning® Premium Options Alert (Actionable) Ticker: $NTLA Contract: Dec 19 $10C Entry: 0.53 Exit: 0.95 Return: +80.34% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
VVDB
VVDB Dec. 4 at 11:02 PM
$NTLA Will explode once FDA restriction for the trial is cancelled. https://youtu.be/T-F5kWyuIXo?si=TfukXsjf7wpd9JtD
0 · Reply
svertical1
svertical1 Dec. 4 at 10:54 PM
$IBRX $CADL $NTLA $CRSP should have doubled today, if not more!
3 · Reply
GoldenBully
GoldenBully Dec. 4 at 9:58 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $NKLR $CL $NTLA $NOW (
0 · Reply
svertical1
svertical1 Dec. 4 at 9:35 PM
$VRTX $CRSP $XBI $NTLA If Vertex makes attempt to buy CRSP, they should offer: • $50 per share in cash ($4B) •1 share of Vertex for every 4 shares of CRSP (25M Vertex shares- or $11.5B) Total offer $15B (Cholesterol drug alone eventually pays for this, 100% rev on CASGEVY helps too) Use another $2B for rare disease Fast Track Trials for dozens of genetic diseases. This is where CRSP dropped the ball…Pipeline should be massive!
1 · Reply
Golden_Steer
Golden_Steer Dec. 4 at 8:53 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $RDW $NKLR $S $NTLA Limited
0 · Reply
svertical1
svertical1 Dec. 4 at 8:01 PM
$VRTX $CRSP $NTLA $EDIT Vertex is clear leader in: CF, SCD, TDT, Pain, Kidney, T1D Imagine then leading genetic engineering after CRSP buy🤞! Use their Billions to begin trials for the Top 100 genetic diseases. Keep 100%!of revenue! All Fast Tracked, with FDA onboard to Insure US Biotech remains preeminent over China and others.
1 · Reply
GoFrogs09
GoFrogs09 Dec. 4 at 6:44 PM
$NTLA was heavily shorted any news will make this run back to $15 👍
0 · Reply
SevenClips
SevenClips Dec. 4 at 6:28 PM
$NTLA any day now...
0 · Reply
3DBuilds
3DBuilds Dec. 4 at 5:06 PM
$CRBU $CRSP $NTLA $PRME $VERV
0 · Reply
Nagnus
Nagnus Dec. 4 at 3:43 PM
$NTLA As i said people close to the fire already know about the FDA letter and accumulating before official PR. Once its out, this is headed back toward $20
2 · Reply
gazza75799
gazza75799 Dec. 4 at 3:40 PM
$NTLA market is buying small caps till the end of December. This goes to 12$ short term,.and probably higher in January. Positioning and scaling in is key
0 · Reply
Rounderssss4
Rounderssss4 Dec. 4 at 3:38 PM
$NTLA
0 · Reply
burbs88
burbs88 Dec. 4 at 3:27 PM
$NTLA It's hard not to be a little nervous as I'm holding what is probably an irresponsible amount of shares at this point, but I feel pretty good about this jumping 70 to 120 percent shortly.
3 · Reply
APman
APman Dec. 4 at 3:24 PM
$NTLA Fuckers know something retain does not.
0 · Reply
gazza75799
gazza75799 Dec. 4 at 3:19 PM
$NTLA bought 20,000 more
1 · Reply
FemaleGermanInvestor
FemaleGermanInvestor Dec. 4 at 2:47 PM
$NTLA on the way to $10 again
0 · Reply
jeojackson
jeojackson Dec. 4 at 2:14 PM
$NTLA Where the F is the FDA letter?
0 · Reply
Alt_Fuel
Alt_Fuel Dec. 4 at 2:13 PM
$PACB ARK's sustained (if trimmed) exposure underscores Wood's belief in PACB's edge in accurate, long-read sequencing, even as the firm rotates into complementary names like $TXG & $NTLA . Investors should monitor PACB's Q4 earnings for adoption updates on Vega. https://x.com/i/grok?conversation=1996545151129280693 History of ARK Investment's Involvement with Pacific Biosciences (PACB) - Cathie Wood's ARK Investment Management, known for its focus on disruptive innovation in sectors like genomics & biotechnology, first entered Pacific Biosciences of California, Inc. (PACB)—a leader in long-read DNA sequencing technology—in Q3 2017. This initial investment aligned with ARK's thesis on the transformative potential of genomic analysis for healthcare, research, & personalized medicine. Over the years, ARK has executed at least 31 transactions in PACB, including 22 buys and 12 sells, reflecting a volatile but conviction-driven approach amid the stock's price swings (from highs above $50 in 2021 to lows near $1 in 2025).
0 · Reply
janed102
janed102 Dec. 4 at 1:29 PM
$NTLA nothing today
0 · Reply